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Abstract 
 
We investigate the self-assembly of a palmitoylated (C16-chain at the N terminus) peptide fragment in 
comparison to the unlipidated peptide EELNRYY based on a fragment of the gut hormone peptide 
PYY3-36. The lipopeptide C16-EELNRYY shows remarkable pH-dependent self-assembly above measured 
critical aggregation concentrations, forming fibrils at pH 7, but micelles at pH 10. The parent peptide 
does not show self-assembly behaviour. The lipopeptide forms hydrogels at sufficiently high 
concentration at pH 7, the dynamic mechanical properties of which were measured. We also show 
that the tyrosine functionality at the C terminus of EELNRYY can be used to enzymatically produce the 
pigment melanin. The enzyme tyrosinase oxidises tyrosine into 3,4-dihydroxyphenylalanine (DOPA), 
DOPA-quinone and further products, eventually forming eumelanin. This is a mechanism of photo-
protection in the skin, for this reason controlling tyrosinase activity is a major target for skin care 
applications and EELNRYY has potential to be developed for such uses. 
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Introduction 
Peptides are becoming increasingly popular for use in therapeutics. Their high selectivity towards 
biological targets, and ability to be incorporated into the body’s natural pathways, whilst minimizing 
toxic side effects, make them an attractive class of biomolecule.1, 2 Many peptide drugs currently on 
the market are peptide hormones that stimulate a biological response, to help control essential bodily 
functions. Examples include insulin for the treatment of diabetes,1 oxytocin to induce labour,3 and 
thymalfasin to act as an adjuvant for both influenza and hepatitis B vaccines.4-7 
 
Our group has recently been studying the conformation and self-assembly of the gut peptide hormone 
PYY3-36 and lipidated8, 9 and PEGylated9 derivatives as well as and the N-terminal domain IKPEAP(GE) 
and its N-terminal palmitoylated derivative.10 PYY3-36 and its derivatives are a promising target for the 
treatment of obesity and type II diabetes. PYY3-36 is an agonist for the Y2 receptor which is a G-protein 
coupled receptor.  
 
Naturally occurring peptides often require modification in order to be successfully used in 
therapeutics, due to their poor chemical and physical stability, and short circulating half-life.2 Several 
half-life extension techniques have been developed thus far, including albumin binding, enzymatic 
degradation prevention, and PEGylation.2 The latter has become less preferred in recent years 
however, because of safety concerns associated with cellular vacuolation in macrophages and in renal 
tubular cells.2, 11 An alternative to PEGylation is lipidation, which involves the attachment of a lipid 
chain, helping to facilitate serum albumin binding and therefore reduce renal filtration.8, 12 
Furthermore, lipidation can be used to increase the stability of the peptide to changes in environment, 
such as pH, temperature, and concentration.13 
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The use of short peptides in the treatment of disease is very attractive due to relative ease of synthesis, 
and also in terms of cost in comparison to larger peptide therapeutics. 14 Truncated peptide fragments 
provide an effective way of investigating peptide behaviour, and can be used to tune self-assembly 
and binding affinity.  
 
We previously investigated the effect of palmitoyl lipidation on self-assembly and conformational 
stability of the gut hormone PYY3-36, at three different positions within the peptide. 8 The peptide 
sequence is shown in Scheme 1a. The peptide was lipidated within the β-turn domain at position 11 
(Ser), and within the α-helical domain at position 17 (Arg), and 23 (Arg). Results showed that lipidation 
enhanced peptide stability against changes in temperature and pH. The position of lipidation also 
influenced self-assembly, with the formation of micelles occurring for the peptide lipidated within the 
α-helical region under certain pH values. Furthermore, gelation was observed for the lipidated 
peptides at higher concentrations, but not for PYY3-36 itself. 8 In another study in collaboration with 
the group of Beck-Sickinger, Castelletto et al. investigated the conformation and self-assembly of PYY3-
36 derivatives lipidated with an octyl chain or short PEG chain at one of two positions (in the -helical 
domain).9 The lipidated and PEGylated peptides adopt coiled-coil conformations, PEGylation 
stabilizing -helical structure at high temperature. Both lipidated peptides formed spherical micelle 
oligomer structures whereas the PEGylated peptides mainly forms monomers in solution.    
 
Recently, our group studied the conformation and self-assembly of the N-terminal lipidated PYY 
fragments IKPEAP and IKPEAPGE in comparison to the parent peptides.10 Both the lipidated peptides 
form spherical micelles above pH-dependent critical micelle concentrations, however the unlipidated 
peptides do not show aggregation behaviour. The lipidated peptides adopt unordered conformations. 
A notable transition to amyloid-like -sheet fibrils occurs upon drying solutions of the lipopeptide 
micelles.10 
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Here we compare the self-assembly properties and anti-cancer activity of the PYY3-36-derived peptide 
EELNRYY and its N-terminally palmitoylated analogue. This sequence traverses the central part of the 
PYY3-36 sequence including part of the -helical domain. We also examine the enzymatic stimulation 
of eumelanin production by EELNRYY. It is well known that tyrosinase activity on tyrosine leads to 
melanin formation.15-17 Our study was inspired by the recent exciting discovery that this activity on 
self-assembling tyrosine-containing tri-peptides generates artificial melanin-like polymer pigment 
particles.18 
The full peptide sequence of PYY3-36 is shown in Scheme 1a, with the peptide to be studied, EELNRYY, 
highlighted in red. The amino acid sequence of the lipidated fragment and the chemical structure is 
shown in Scheme 1b. The structure of the peptide itself is shown in the SI (Scheme S1). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. a) Amino acid sequence and chemical structure of PYY3-36, showing the 
different domains, and highlighting EELNRYY. b) Amino acid sequence and chemical 
structure of C16-EELNRYY. 
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Methods 
Materials. Palmitoyl-EELNRYY (ammonium acetate salt) was synthesised by Peptide Synthetics, 
Fareham. UK. HPLC and ESI-MS data were obtained with an Agilent 1100 HPLC linked to an Agilent 
1100 MSD Model G1946D. The molecular mass by ESI-MS was 1224.451 g mol-1 (expected 1223.68 g 
mol-1), with a purity of 96.4 % determined by HPLC using a Kinetex XB-C18 2.6 m 100 Å column and 
an acetonitrile gradient. 
EELNRYY (TFA salt) was synthesised by Peptide Synthetics, Fareham. UK. HPLC and ESI-MS data were 
obtained with an Agilent 1100 HPLC linked to an Agilent 1100 MSD Model G1946D. The molecular 
mass by ESI-MS was 986.031 g mol-1 (expected 985.45 g mol-1), with a purity of 95.3 % determined by 
HPLC determined by HPLC using a Kinetex XB-C18 2.6 m 100 Å column and an acetonitrile gradient. 
The manufacturer’s HPLC and ESI-MS data are included in SI Figure 1 – SI Figure 4. 
Pigment preparation.  The activity of tyrosinase on tyrosine to produce melanin is well known.15, 16, 18, 
19   Here, the enzymatic action of tyrosinase on tyrosine was used to prepare a pigment using the 
peptide EELNRYY as tyrosinase substrate. 0.2 wt% tyrosinase from mushroom (Sigma-Aldrich, UK) was 
dissolved in 50 mM potassium buffer (pH 6.8).  
Preliminary assays were also performed using C16-EELNRYY. For these experiments, a mother solution 
containing C16-EELNRYY in 50 mM potassium buffer (pH 6.8) was titrated with the 0.2 wt% tyrosinase 
solution, to obtain 1 wt% C16-EELNRYY + 0.02 wt% tyrosinase. As discussed later in the manuscript, 
preliminary assays on C16-EELNRYY were relatively unsuccessful and lead us to focus on EELNRYY. 
A mother solution of EELNRYY in 50 mM potassium buffer (pH 6.8) was titrated with the 0.2 wt% 
tyrosinase solution, to obtain a final solution containing 1 wt% EELNRYY + 0.02 wt% tyrosinase. After 
mixing, two separate aliquots of the EELNRYY/tyrosinase solution were left to rest for 24 or 48 hrs in 
the dark, at room temperature. Brown solutions were obtained after 24 or 48 hrs, and then 
centrifuged at 15000 rpm for 10 mins. A pellet and a supernatant were obtained after centrifugation. 
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Both the pellet and the supernatant were brown, indicating the presence of eumelanin.  The 
supernatant was recovered and analysed using SAXS, MALDI, UV-vis and NMR.  
Fluorescence Spectroscopy. The critical aggregation concentration (cac) values were determined at 
room temperature (20 oC) using a Varian Cary Eclipse fluorescence spectrometer with samples in 4 
mm inner quartz cuvettes. Pyrene was used as the fluorescent probe, and assays were performed 
using 1.0 x10-2 to 0.3 wt% peptide, in 2.167 x 10-5 wt % pyrene solution. The samples were excited at 
λex = 339 nm, and the fluorescence emission was measured for λ = 360−500 nm. Dityrosine formation 
was investigated at native pH (pH 7) and pH 12. Fluorescence experiments were measured for water 
and 0.1 wt% peptide solutions. Samples were measured in a 1.0 cm path-length quartz cuvette, and 
the slit width was 5 nm. Emission spectra were recorded at λex = 315 nm from 340 to 600 nm, and 
excitation spectra were recorded at λem = 410 nm, from 250-410 nm. Five measurements were taken 
for each spectrum, and the background was subtracted. 
Circular Dichroism (CD). CD spectra were recorded using a Chirascan spectropolarimeter (Applied 
Photophysics, UK). Spectra are presented with absorbance A < 2, with a 0.5 nm step, 1 nm bandwidth, 
1 s collection time per step, and 3 repeats. The CD signal from the background (water) was subtracted 
from the CD signal of the sample solution. Ellipticity is reported as the mean residue ellipticity ([θ], in 
deg cm2/dmol) calculated as: 
[θ] = [θ]obs MRW/10cl 
Where [θ]obs is the ellipticity measured in millidegrees, MRW is the mean residue molecular weight of 
the peptide (molecular weight divided by the number of amino acid residues), c is the concentration 
of the sample in mg/mL, and l is the optical path length of the cell in centimeters. 
Samples were placed in quartz plaques (0.1 mm spacing) with 1 wt% peptide concentration in the pH 
range 9-10. CD spectra were measured using a temperature range of 20-70 o C with 10 o C increments. 
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Each sample was equilibrated at each temperature for 2 minutes before measurements were 
recorded.  
UV-vis Absorption. Spectra were recorded using a Varian Cary 300 Bio UV/Vis spectrometer. Samples 
were analyzed in quartz cuvettes with a 5.0 mm path length and were baseline corrected with respect 
to a blank cell with the appropriate solvent. 
Cryogenic Transmission Electron Microscopy (cryo-TEM). Imaging was carried out using a field 
emission cryo-electron microscope (JEOL JEM-3200FSC) operating at 200 kV. Images were taken using 
bright-field mode and zero loss energy filtering (omega type) with a slit width of 20 eV. Micrographs 
were recorded using a CCD camera (Gatan Ultrascan 4000, USA). The specimen temperature was 
maintained at -187 oC during the imaging. Vitrified specimens were prepared using an automated FEI 
Vitrobot device using Quantifoil 3.5/1 holey carbon copper grids, with a 3.5 μm hole size. Grids were 
cleaned using a Gatan Solarus 9500 plasma cleaner just prior to use and then transferred into the 
environmental chamber of a FEI Vitrobot at room temperature and 100% humidity. Following this, 3 
μL of sample solution at 1 wt % concentration was applied on the grid, blotted once for 1 s, and then 
vitrified in a 1:1 mixture of liquid ethane and propane at −180 °C. Grids with vitrified sample solutions 
were maintained in a liquid nitrogen atmosphere and then cryo-transferred into the microscope. Swith 
1 wt% concentration were imaged. 
Small Angle X-ray Scattering (SAXS). Solution SAXS measurements were carried out on the bioSAXS 
beamline B21 at Diamond, Harwell, UK. (Lipo)peptide solutions (1 wt% concentration) or EELNRYY + 
tyrosinase solutions, were loaded into PCR tubes in an automated sample changer. Data was collected 
using a 2 M detector and at a fixed camera length of 3.9 m with a wavelength λ = 1 Å. The wavenumber 
q = 4π sin θ /λ scale was calibrated using silver behenate, where λ is the x-ray wavelength and 2θ is 
the scattering angle. Gel samples were mounted in a custom-designed multi-purpose sample holder 
for gels and pastes.20 Measurements were performed at room temperature (20 oC). 
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Rheology. Gel properties were investigated using an AR-2000 rheometer. Experiments were 
performed at room temperature using a plate- plate geometry (plate radius = 20 cm; gap = 400 μm). 
The linear viscoelastic regime of the sample was first identified from the dependence of the storage 
(G′) and loss (G″) moduli on the oscillation strain at a fixed frequency of 1 Hz. The dependence of G′ 
and G″ on the angular frequency was then determined at a fixed oscillatory strain of 0.6 % within the 
linear regime. 
Mass spectrometry. Samples were defrosted at room temperature for 5 minutes, then analysed by 
liquid atmospheric pressure matrix-assisted laser desorption/ionization (AP-MALDI) mass 
spectrometry (MS)21, 22 An aliquot of α-Cyano-4-hydroxycinnamic acid (CHCA) was dissolved in 
acetonitrile/water (70:30) by 2-minutes sonication to a final concentration of 30 mg/ml. Once CHCA 
was completely dissolved, this solution was diluted with ethylene glycol in a ratio of 10:7 
(v[solution]:v[ethylene glycol]), vortexed for 5 seconds and sonicated for 1 minute to make the liquid 
support matrix (LSM). Each sample was subsequently mixed 1:1 (v:v) on the MALDI target (1.4 µl final 
volume) with the LSM just before analysis, obtaining a stable droplet lasting for >1h. 
Mass spectrometry analysis was performed using a Synapt G2-Si mass spectrometer (Waters 
Corporation, Wilmslow, UK) modified with an in-house developed AP-MALDI ion source as previously 
described.23 Briefly, the ion source incorporates a heated ion transfer tube for enhanced MALDI plume 
desolvation conditions. The ion transfer tube temperature was set to 80° C, the cone voltage to 40 V 
and the applied counter N2 gas flow (in opposite direction to the vacuum flow) was set to 180 L/h. The 
samples were radiated with a pulsed nitrogen laser (337 nm, 3ns; MNL 103 LD; LTB Lasertechnik 
GmbH, Berlin, Germany) using a pulse energy of ~20 µJ per shot focused to a diameter of 
approximately 100-150 μm with a pulse repetition frequency of 20Hz. Each sample was analysed in 
duplicate with a data acquisition time of 2 minutes in positive ion MS sensitivity mode with ion 
mobility and a scan rate of 1 TOF scan per second, recording an m/z range of 100-2000 using MassLynx 
V 4.1 software (Waters). 
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Nuclear Magnetic Resonance (NMR). The supernatant obtained from a EELNRYY/tyrosinase sample 
incubated for 24rs, prepared as described above, was freeze dried. The lyophilized brown powder, 
obtained after freeze drying, was dissolved in D2O at a concentration of 0.5 wt% EELNRYY+0.01 wt% 
tyrosinase. The resulting solution was then filtered using an Anotop filter (WhatmanTM, pore size 0.02 
uM).  NMR experiments were performed on the filtered solution. The NMR spectra were recorded 
using a Bruker Avance III spectrometer (Bruker, Germany), equipped with a four channel Bruker 
cryoprobe, operating at a Larmor 1H frequency of 700.19 MHz (16.44T) and 13C frequency of 176.08 
MHz. The 1H spectra were recorded using a pre-saturation method during the relaxation delay (RD) 
and mixing time (tm) using a standard Bruker noesypr1d pulse sequence. The 90° pulse was 9.25 μs at 
the power level of 8.3 W. The tm was set to 0.06 s. A total of 64 transients were recorded with a 
relaxation delay of 3 s and averaged into each spectrum.  The proton decoupled 13C experiments 
required 4096 transients, and were recorded with 20 s relaxation delay. The 2D spectra (e.g. COSY, 
TOCSY, HSQC and HMBC) were also recorded to confirm the assignments of the peaks to the molecular 
structure. The indirect (F1) dimension of the 2D experiments was set to 256 points and between 8 
(COSY) and 64 (HMBC) transient were average into each indirect point.  All spectra were referenced 
using external a TMS reference signal at 0 ppm.  
Results and Discussion 
We first investigated the presence of a critical aggregation concentration (cac), using pyrene as a 
fluorescent probe. Pyrene is a fluorophore sensitive to hydrophobic environments, and in the 
presence of such environment it becomes encapsulated inside to cause a distinct increase in the 
absorbance intensity.24, 25 Pyrene has been widely used to detect critical aggregation concentrations 
of peptides and amphiphilic molecules.26-27 A plot of the I1 (373 nm) intensity versus concentration 
may be used to assign the cac, with the I1 peak corresponding to the first vibronic band of pyrene. The 
cac is defined by the intersections of the two lines, and results indicate an increase in cac with 
increased pH with values of (0.0044 ± 0.001) wt%, (0.046 ± 0.002) wt% and (0.150 ± 0.002) wt% at pH 
11 
 
7, 10, and 12 respectively for C16-EELNRYY (Figure 1a). The increase in cac with pH indicates reduced 
hydrophobicity at pH 12, presumably due to the presence of tyrosinate ions at high pH. No cac was 
observed for the unlipidated peptide fragment itself, demonstrating a lack of aggregation. The 
increased amphiphilicity caused by the alkyl chain helps to drive aggregation, as a result of the 
hydrophobic effect.28-29  
Circular dichroism spectroscopy was used to examine the secondary structure of the native and 
lipidated peptides at pH 9 and 20 o C, at a concentration above the cac of C16-EELNRYY in order to 
investigate conformation under conditions of assembly. At pH 9 and above solutions of both peptides 
were clear, but below this pH, the lipidated peptide formed a precipitate. CD spectra are shown in 
Figure 1b. The native peptide appears to have a disordered secondary structure with a minimum at 
195 nm, whilst the lipidated truncated fragment shows a spectrum characteristic of a -sheet 
structure with a minimum at around 218 nm, and positive ellipticity at 195 nm (Figure 1b). The spectra 
for EELNRYY at two different pH values are shown in Figure S5, the spectra at pH 2.5 reveals the 
presence of very little secondary structure. Temperature ramp experiments were also carried out for 
C16-EELNRYY from 20-70 o C, and the results show that the beta-sheet structure is retained throughout 
this temperature range (Figure S6a). A further CD experiment was performed to study the pH stability 
of the 
Figure 1. a) Fluorescence using pyrene to determine the critical aggregation concentration (cac) 
of C16-EELNRYY at pH 10 and pH 12. The point of intersection defines the cac. I1= the intensity 
value at 373 nm. b) CD spectra of C16-EELNRYY and EELNRYY at 1 wt%, 20 o C and pH 9. 
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lipidated peptide in the pH range 7 (native pH) to pH 12. The spectra are shown in Figure S6b.  At high 
pH, tyrosine becomes charged tyrosinate, the conjugate phenolate base of tyrosine, and the resulting 
CD spectra shows a significantly reduced molar ellipticity, that is only partially reversible upon 
returning the pH back to 7. This indicates that the peptide undergoes irreversible disaggregation in 
highly alkaline conditions. At pH 12, the peptide carries a highly negative charge of -6, calculated using 
innovagen software;30 therefore charge repulsion was expected to interrupt secondary structure. 
Results confirm this, and upon pH change from pH 7 to pH 12, there is a transition in secondary 
structure from β-sheet to disordered. Lowering the pH back down to 7 indicates only partial 
reversibility back to β-sheet, with molar ellipticity values at the 216 nm minimum that are much less 
negative than before the pH change.  
 
Cryo-TEM and SAXS were used to examine self-assembly at a concentration above the cac of C16-
EELNRYY. Cryo-TEM images of C16-EELNRYY revealed fibers at native pH (pH 7), strings of micelles at 
pH 10, and nanosheets at pH 12 (Figure 2). As expected, no defined structures were observed for 
EELNRYY since it does not have a cac, and representative images are shown in Figure S4. SAXS was 
used to compliment cryo-TEM, and the scattering intensity profiles for C16-EELNRYY are shown in 
Figure 2d. (those of EELNRYY are shown in Figure S8). The SAXS data for C16-EELNRYY was fitted to a 
long cylindrical shell form factor at pH 7 (native pH), and a spherical shell form factor at pH 10, 
representative of fibers and micelles respectively. The data at pH 12 was fitted to a combination of a 
bilayer Gaussian and generalized Gaussian coil form factor. This was due to cryo-TEM images revealing 
the presence of nanosheets, but the SAXS intensity profile indicating a mixture of monomers and 
nano-sheets.  The SAXS data for native peptide, EELNRYY was fitted to a generalized Gaussian coil form 
factor, corresponding to monomers. There is a significant structure factor peak at q = 0.05 Å-1 for C16-
EELNRYY at pH 10, indicating interactions between the micelles, consistent with cluster formation as 
revealed in the cryo-TEM images.  Tables of fitted parameters are shown in Tables S1-S5. 
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The possibility of dityrosine formation in alkaline conditions (pH 12) was investigated using 
fluorescence spectroscopy. Dityrosine is easily recognised by an intense fluorescence peak at 400 nm 
in the emission spectrum, representative of its singly ionized form, and by a peak at 315 nm in the 
exciation spectrum under alkaline conditions. The emission and excitation spectra of C16-EELNRYY are 
Figure 2. cryo-TEM and SAXS of C16-EELNRYY at 1 wt% in H2O. a) cryo-TEM images at native pH 
(pH 7) showing fibers, b)  cryo-TEM images at pH 10 showing strings of micelles, c) cryo-TEM 
images at pH 12 showing nanosheets, d) SAXS intensity profiles and form factor fittings in the 
pH range 7-12. Data was fitted to a long cylindrical shell form factor at pH 7, a spherical shell i 
at pH 10, and a combination of generalized Gaussian coil and bilayer Gaussian at pH 12.  
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shown in Figure S9. At pH 12, the emission spectrum shows enhanced intensity around 400 nm, 
showing some dityrosine formation, and this is not present at native pH. This is because at high pH, 
the phenol hydroxyl group becomes deprotonated to form phenolate ions. The excitation spectrum 
also agrees with dityrosine formation due to a red shift of the peak position from around 300 nm to 
320 nm. Fluorescence spectra for the unlipidated peptide also show dityrosine formation (Figure S10). 
 
Peptide hydrogels may be useful for applications such as slow drug release delivery systems, or for 
the topical application of therapeutic peptides, or encapsulated drugs. Hydrogel formation by 
lipidated peptides is rather uncommon, and few studies have been reported so far in comparison to 
unlipidated -sheet peptides.31 In one example reported, it has been found that β-sheet nanofiber 
forming lipidated peptides can aggregate into gels via noncovalent intermolecular cross-linking.32, 33 A 
further example studied within our group, observed gelation with three lipidated derivatives of PYY3-
36, all of which formed gels. The peptides had an α-helical secondary structure in solution, with a 
transition to β-sheet occurring above 50 o C at a specific pH value. A combination of this and increased 
concentration allowed for gelation to occur.8 
 
Since C16-EELNRYY was found to adopt a β-sheet structure, it was of interest to investigate its gelation 
properties. Increasing the concentration to 1 wt% and above allowed for the formation of a hydrogel, 
the gel forming at the peptide’s native pH in ultrapure water (pH 7) (Figure S11). It is noteworthy that 
the gel forms without requiring pH adjustment or the addition of buffer. The theoretical isoelectric 
point calculated using Innovagen software, was 4.15, with the net charge being -1 at pH 7.30 At pH 7, 
the electrostatic charges are easily overcome, allowing the hydrophobic interactions, and π-π stacking 
of the tyrosine residues to drive gelation. It is however important to note that the pKa values in 
peptides can shift upon aggregation, meaning that the exact charge on amino acid residues is very 
hard to quantify fully.34, 35 Gelation was not observed for the EELNRYY peptide itself. Incorporation of 
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a hydrophobic alkyl chain to the peptide enables the formation β-sheet structure.36 Therefore a 
combination of increased hydrophobicity, and π-π stacking of the tyrosine motifs was suggested to be 
the mechanism behind gelation. 
CD and fiber X-ray diffraction (XRD) were used to study conformation within the gel, along with SAXS 
and TEM to probe the morphology. Rheology was then used to determine the viscoelastic properties 
of the gel. The strain sweep shows linear viscoelastic behaviour up to around 1 % strain, and the 
frequency sweep at a fixed strain of 0.6 % displays a lack of strain dependence on frequency. 
Furthermore, G’ > G”, and the magnitude of G’ is significantly high compared to a fluid, consistent with 
a gel-like nature (Figure 3). The value of G’ ~ 100 kPa actually indicates a hard gel structure.  
 
 
 
CD spectra for the gel of the lipidated peptide fragment at pH 7, from 20-70 o C are shown in Figure 
4a, and the spectra show a β-sheet like spectrum with a minimum close to 210 nm across this 
temperature range. Fiber XRD intensity profiles for a sample prepared by drying a gel are shown in 
Figure 4b and the results indicate a β-sheet structure for both the lipidated and native peptide, 
Figure 3. a) Dependence of shear moduli G′ and G″ on a) oscillatory strain and b) angular 
frequency for a gel of C16-EELNRYY (1 wt% sample). 
16 
 
showing d-spacings of 4.68 Å that are associated with the spacing of β-strands in a “cross- β” pattern. 
This is a very interesting result as it implies that the native peptide forms β-sheet structures upon 
drying, compared to a disordered structure in solution. TEM images of the peptide gel show a network 
of entangled fibers (Figure 4c). The SAXS intensity profile of the gel is shown in Figure 4d and data was 
fitted to a long cylindrical shell form factor, typically used for fibrils (Table S6). This data together 
shows that C16-EELNRYY forms -sheet based gels and that the -sheet structure is present on drying 
the samples 
 
 
 
Figure 4. a) CD spectra obtained for a gel of C16-EELNRYY at pH 7 from 20-70 o C. b) Fibre X-ray 
diffraction intensity profile of EELNRYY and C16-EELNRYY at native pH, with peaks with d = 4.68  Å 
indicated. c) TEM images of C16-EELNRYY gel showing a network of fibers at native pH. d) SAXS 
data of C16-EELNRYY gel fitted to a long cylindrical shell form factor. 
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The preceeding results show that addition of the hexadecyl lipid chain drives self-assembly of 
EELNRYY, which itself does not self-assemble. This is confirmed by the absence of a cac, cryo-TEM 
(Figure S7), SAXS (Figure S8) and the disordered CD spectrum (Figure 1b and Figure S5). We 
investigated the possibility of melanin production via tyrosinase enzyme activity, using this non-self-
assembling peptide. The presence of two C-terminal tyrosine residues suggests the potential of 
EELNRYY to serve as a substrate for enzymatic modification with tyrosinase. The enzyme tyrosinase 
from mushroom oxidises tyrosine into 3,4-dihydroxyphenylalanine (DOPA), DOPA-quinone and 
further products (Figure S12), eventually forming eumelanin.15-17, 37 Eumelanin is the main component 
of melanin pigmentation in skin, hence the tyrosine-tyrosinase reaction is one of the major targets in 
cosmetic formulations, which represents another potential use of EELNRYY.  
We first performed an assay using C16-EELNRYY as a substrate for the enzymatic oxidation using 
tyrosinase. 1 wt% C16-EELNRYY in 50 mM potassium buffer (pH 6.8) is a transparent hydrogel, similar 
to that shown in Figure S11. After 24 hrs incubation of 1 wt% C16-EELNRYY with 0.02 wt% tyrosinase a 
pale brown hydrogel was produced (Figure 5b). The weak change in colour and viscoelasticity of the 
sample after 24 hrs treatment, indicates that C16-EELNRYY as a poor substrate for tyrosinase. 
Therefore, we used EELNRYY for further studies. 
A solution of 1 wt% EELNRYY in 50 mM potassium phosphate (pH 6.8) is transparent, as shown in 
Figure 5a. The incubation of 1 wt% EELNRYY + 0.02 wt% tyrosinase in 50 mM potassium buffer (pH 
6.8) for 24 hrs, produced a dark brown solution which could be separated into a precipitate and a 
supernatant after centrifugation. Figure 5c shows that the supernatant still has a dark brown colour, 
due to the rich content of eumelanin, even after centrifugation.  
UV-visible spectroscopy was used to qualitatively confirm eumelanin production. The UV-vis spectrum 
measured for the solution in Figure 5c, diluted 33 fold, (Figure S12a) displays a monotonic increase in 
radiation absorption at lower wavelengths, a typical behaviour and one of the most important 
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features of melanins.37 The peak at ~ 280 nm is related to tyrosine residues38 in the unreacted 
EELNRYY.  
The nanostructure within the EELNRYY sample treated with tyrosinase was studied by SAXS and 
compared to the nanostructure of the pure peptide solution. Figure S12b displays the SAXS curves for 
the supernatant of an EELNRYY/tyrosine solution incubated for 24 hrs and a pure EELNRYY control 
solution, fitted to a generalized Gaussian coil form factor. The SAXS data for the control tyrosinase 
solution (0.02 wt% tyrosinase in 50 mM potassium phosphate; pH 6.8) is not included in Figure S12b 
because the concentration was too low to provide reliable SAXS data. The parameters extracted from 
the fitting to the SAXS data in Figure S12b are listed in Table S7. The radius of gyration Rg for the 
sample containing only EELNRYY corresponds to monomers in solution, in good agreement with 
results listed in Table S2.  The Rg is higher for EELNRYY/tyrosinase samples, indicating oligomeric 
aggregation consistent with the visible pigment particles present in the solution (Figure 5c). 
 
 
 
 
 
 
 
 
Figure 5. Images of (a) 1 wt% C16-EELNRYY + 0.02 wt% tyrosinase, (b) 1 wt% EELNRYY sol and (c) 1 wt% 
EELNRYY + 0.02 wt% tyrosinase. Samples in (a-c) were dissolved in 50 mM potassium phosphate (pH 
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6.8). The 1 wt% C16-EELNRYY in 50 mM potassium phosphate (pH 6.8) sample is not shown because it 
is a transparent hydrogel similar to that displayed in Figure S8. 
 
MS analysis was also used to further the understanding of the formation of the DOPA and DOPA-
quinone molecular forms of the peptide EELNRYY (structures shown in Scheme S2). Due to the high 
tolerance of liquid (AP-) MALDI for salts and buffers, allowing the rapid analysis of salt- and buffer-rich 
peptide samples with no pre-fractionation or clean-up steps,39, 40 this newly developed ionisation 
technique was employed for direct MS analysis of phosphate buffer-rich assay solutions. Samples 
containing 1 wt% EELNRYY and 0.02 wt% tyrosinase in 50 mM potassium phosphate (pH 6.8) were 
prepared as described in the experimental section and incubated in the dark at room temperature for 
24h and 48h. Small aliquots from the samples of these two time points and from 1 wt% EELNRYY in 50 
mM potassium phosphate (pH 6.8) left in the dark at room temperature for 24h were analysed by 
liquid AP-MALDI MS as described in the experimental section. The MS data obtained from these three 
samples are shown in Figure 6. 
The spectra in Figure 6 clearly show the generation of EELNRYY-DOPA (monoisotopic mass of 
1017.4403 Da) and EELNRYY-DOPA-quinone (monoisotopic mass of 1013.4090 Da) when incubated 
with 0.02 wt% tyrosinase in 50 mM potassium phosphate. Both protonated peptide forms are clearly 
visible after 48h at m/z 1018.43 and m/z 1014.38 (Fig. 6c) while after 24h (Fig. 6b) substantially more 
ion signal for EELNRYY-DOPA and the mono-oxidized peptide (m/z 1002.44) was detected, indicating 
a kinetic profile that is staged, starting with the oxidation of one tyrosine residue and the subsequent 
oxidation of the second tyrosine before the formation of the quinone. However, it should be noted 
that a strong signal for a molecular ion approximately 4 Da lower in mass than the mono-oxidized 
peptide was also detected after 48h. Thus, this data provides further support to the postulated 
synthesis of eumelanin by tyrosinase oxidation of tyrosine,37 where it is expected that the EELNRYY-
DOPA precursor is formed before the generation of EELNRYY-DOPA-quinone. 
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Figure 6. Liquid AP-MALDI mass spectra of 1 % (w/v) EELNRYY in 50 mM potassium phosphate: a. after 
24h incubation without tyrosinase; b. after 24h incubation with 0.02 % (w/v) tyrosinase; c. after 48h 
incubation with 0.02 % (w/v) Tyrosinase. All spectra were recorded in positive ion mode. 
 
Furthermore, cleavage/fragmentation of the peptide leading to the production of a-type and b-type 
fragment ions was also observed (Fig. 6b and c), for fragment ion nomenclature see ref.41 Interestingly, 
only fragment ions indicating the loss of the C-terminal tyrosine or both tyrosine residues were 
detected, the latter being the dominant fragment ion signal after 48 h. This degradation (and other 
time-dependent losses, e.g. due to surface adsorption) can explain the generally lower ion signals of 
the peptide and its DOPA and quinone products after 48h. The comparison of the 24 h data obtained 
with and without tyrosinase incubation (Fig. 6a and b) clearly suggests that tyrosinase incubation 
promotes C-terminal proteolytic activity. It has been suggested that such peptide cleavage can result 
from contamination of commercial mushroom tyrosinase with peptidases.42 
 
 
NMR was used to investigate the species in solution for a sample containing 0.5 wt% EELNRYY+ 0.01 
wt% tyrosinase, prepared from the solution shown in Figure 5b, as described in the Experimental 
Section. Table S8 shows the NMR resonances and their assignment to the EELNRYY molecule, while 
Table S9 shows the estimation of NMR resonances for EELNRYY and EELNRYY treated with tyrosinase. 
Figure S11 shows the 1H NMR spectrum measured for a 2 wt% EELNRYY solution compared to the 
same spectrum measured for the 0.5 wt% EELNRYY+ 0.01 wt% tyrosinase solution. The spectra for 
0.5% EELNRYY + 0.01 wt% tyrosinase has a large number of additional resonances which are not 
present in the spectra for 2 wt% EELNRYY (Figure S13). Highlighted additional resonances are as 
follows:  in the  1H spectrum resonances between 6.3 - 7.5ppm and 3.2 -  3.9ppm; in the 13C spectrum 
resonances between 180 – 170ppm, 160 – 140ppm,  134 – 133ppm, ca. 129.7ppm, ca. 118.7ppm, 80 
– 70ppm, 60 – 57ppm and ca. 38.3ppm (results not shown).  The existence of these additional 
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resonances may indicate the presence of distinct conformations and/or various shorter EELNRYY 
fragment peptide, especially involving loss of a C-terminal tyrosine. The additional doublets in Figure 
S11 are consistent with the latter, suggesting that tyrosinase has additional activity in cleavage of the 
C-terminal residue as well as modification to the DOPA and DOPA-quinone structures shown in Figure 
S9.  However, detailed analysis is not justified as they are only present at an impurity level of ca. 0.05% 
(main signal 99.95%). In addition, NMR was unable to prove on its own, modifications to the tyrosine 
rings in the lower peptide concentration 0.5 wt% EELNRYY+ 0.01 wt% tyrosinase solution. There is 
some evidence for changes induced involving carbons C1 and C24, C2 and C23 and  C3 and C22, C5 
and C26 carbons  (following labelling in Tables S8-S9), but the intensity is only 0.03% at the impurity 
level.  
Conclusions 
The self-assembly of an N-terminal lipidated peptide fragment of the Y2-receptor agonist peptide 
hormone PYY3-36 has been examined, and compared to the unlipidated fragment. Fluorescence studies 
using pyrene were used to locate the cac of C16-EELNRYY which was pH-dependent. However, no cac 
was obtained for EELNRYY, consistent with lipidation enhancing amphiphilicity and hence aggregation 
propensity. Circular dichroism spectroscopy shows distinct differences between the lipidated peptide 
and the native peptide, the lipidated peptide having a β-sheet secondary structure at pH 9 and the 
native having a disordered structure. Cryo-TEM and SAXS of the lipidated peptide showing a range of 
aggregated structures from strings of micelles, to fibrils, to nanosheets depending on pH. In contrast, 
no distinct aggregated structures were observed for the native peptide. Dityrosine formation was 
confirmed via fluorescence spectroscopy at very high pH 12. The ability to tune the self-assembled 
structure by pH control is a remarkable feature of C16-EELNRYY aggregation, and this is not observed 
for other PYY-derived lipopeptides C16-IKPEAP and C16-IKPEAPGE10 and also not for the parent PYY3-36 
peptide, although lipidated PYY3-36 derivatives do form spherical micelles,9, 43 and palmitoylated PYY3-
36 peptides form both spherical micelles and fibrils dependent on pH (dependent on the position of 
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lipidation).43 Opposite to C16-EELNRYY, some lipidated PYY3-36 derivatives self-assemble into spherical 
micelles at low pH and fibrils at higher pH.43 
 
Unexpectedly, the lipidated peptide was found to form a hydrogel at native pH (pH 7) at 1 wt% 
concentration. The mechanism behind gelation was the formation of β-sheet structure, allowing for 
the formation of a network of fibrils. Rheological studies provided quantitative evaluation of the shear 
moduli for the gel structure, which is actually a hard with a shear modulus G’ ~ 100 kPa, which may be 
advantageous for slow release delivery systems or specific tissue engineering applications. 
 
We observe the formation of eumelanin pigment due to tyrosinase activity on EELNRYY. Notably, the 
melanin production is observed for a non-assembling peptide, in contrast to the findings of Ulijn and 
coworkers on Y-containing self-assembling tripeptides.18 Our results indicate that aggregation (i.e. 
presentation of the tyrosine motif in a regular high density fashion) is not a necessary requirement for 
tyrosinase production of eumelanin pigment in short tyrosine-functionalized peptides. 
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